Takeda Trial for Crohn's Perianal Fistulas Treatment Misses Primary Endpoint
By Ben Glickman
Takeda said Tuesday its trial of darvadstrocel in the treatment of complex Crohn's Perianal Fistulas didn't meet its primary endpoint based on topline data.
The pharmaceutical company said the Phase 3 trial assessing the treatment, which goes by brand name Alofisel, had a primary endpoint of combined remission at 24 weeks.
The company said it was evaluating the financial effect of the study results, which may include impairment loss for intangible assets in the fiscal quarter ended Sept. 30.
Takeda said Alofisel had already been approved in the European Union, Israel, Switzerland, Serbia, the U.K. and Japan based on data from a previous trial, with approval in Japan also based on an additional trial.
Full results from the study will be presented at a future medical meeting or published in a journal.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
October 17, 2023 20:02 ET (00:02 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing